Ueda, K.; Uemura, K.; Ito, N.; Sakai, Y.; Ohnishi, S.; Suekane, H.; Kurose, H.; Hiroshige, T.; Chikui, K.; Nishihara, K.;
et al. Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma. Curr. Oncol. 2024, 31, 1701-1712.
https://doi.org/10.3390/curroncol31040129
AMA Style
Ueda K, Uemura K, Ito N, Sakai Y, Ohnishi S, Suekane H, Kurose H, Hiroshige T, Chikui K, Nishihara K,
et al. Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma. Current Oncology. 2024; 31(4):1701-1712.
https://doi.org/10.3390/curroncol31040129
Chicago/Turabian Style
Ueda, Kosuke, Keiichiro Uemura, Naoki Ito, Yuya Sakai, Satoshi Ohnishi, Hiroki Suekane, Hirofumi Kurose, Tasuku Hiroshige, Katsuaki Chikui, Kiyoaki Nishihara,
and et al. 2024. "Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma" Current Oncology 31, no. 4: 1701-1712.
https://doi.org/10.3390/curroncol31040129
APA Style
Ueda, K., Uemura, K., Ito, N., Sakai, Y., Ohnishi, S., Suekane, H., Kurose, H., Hiroshige, T., Chikui, K., Nishihara, K., Nakiri, M., Suekane, S., Ogasawara, S., Yano, H., & Igawa, T.
(2024). Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma. Current Oncology, 31(4), 1701-1712.
https://doi.org/10.3390/curroncol31040129
